Synergistic effects of Alpelisib (PI3K inhibitor) and Ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models
- Van Schaeybroeck, S. (Examiner)
Activity: Examination types › PhD external examination
Activity: Examination types › PhD external examination